Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 3.06
(3.55%)
SEK 3.06
(3.55%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.32 Million SEK | 46.29% |
| 2022 | 19.36 Million SEK | 47.58% |
| 2021 | 13.11 Million SEK | 363.84% |
| 2020 | 2.82 Million SEK | 1356.14% |
| 2019 | 194.25 Thousand SEK | 5410.64% |
| 2018 | 3525.00 SEK | -3.56% |
| 2017 | 3655.00 SEK | -16.84% |
| 2016 | 4395.00 SEK | -99.2% |
| 2015 | 548.18 Thousand SEK | -6.04% |
| 2014 | 583.4 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.43 Million SEK | 3.64% |
| 2024 Q2 | 6.82 Million SEK | 25.71% |
| 2023 Q4 | 5.24 Million SEK | 1.81% |
| 2023 Q3 | 5.14 Million SEK | 15.3% |
| 2023 FY | 28.31 Million SEK | 46.23% |
| 2023 Q1 | 2.26 Million SEK | -42.66% |
| 2023 Q2 | 4.46 Million SEK | 97.11% |
| 2022 Q2 | 3.64 Million SEK | -23.19% |
| 2022 Q1 | 4.74 Million SEK | 121.25% |
| 2022 FY | 19.36 Million SEK | 47.58% |
| 2022 Q4 | 3.95 Million SEK | -43.77% |
| 2022 Q3 | 7.02 Million SEK | 92.98% |
| 2021 Q3 | 6.75 Million SEK | 271.34% |
| 2021 Q2 | 1.81 Million SEK | -24.36% |
| 2021 FY | 13.11 Million SEK | 363.84% |
| 2021 Q1 | 2.4 Million SEK | -7.39% |
| 2021 Q4 | 2.14 Million SEK | -68.27% |
| 2020 Q1 | 4900.00 SEK | 0.0% |
| 2020 FY | 2.82 Million SEK | 1356.14% |
| 2020 Q4 | 2.59 Million SEK | 1098.93% |
| 2020 Q3 | 216.57 Thousand SEK | 1948.92% |
| 2020 Q2 | 10.57 Thousand SEK | 115.71% |
| 2019 FY | 194.25 Thousand SEK | 5410.64% |
| 2018 FY | 3525.00 SEK | -3.56% |
| 2017 FY | 3655.00 SEK | -16.84% |
| 2016 FY | 4395.00 SEK | -99.2% |
| 2015 FY | 548.18 Thousand SEK | -6.04% |
| 2014 FY | 583.4 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.129% |
| AcouSort AB (publ) | 25.87 Million SEK | -9.47% |
| Active Biotech AB (publ) | 44.8 Million SEK | 36.784% |
| Alzinova AB (publ) | 36.39 Million SEK | 22.172% |
| Amniotics AB (publ) | 29.07 Million SEK | 2.565% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -93.314% |
| BioArctic AB (publ) | 89.62 Million SEK | 68.395% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.327% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.233% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -29.374% |
| Genovis AB (publ.) | 88.19 Million SEK | 67.883% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.384% |
| Mendus AB (publ) | 129.13 Million SEK | 78.065% |
| Kancera AB (publ) | 63.07 Million SEK | 55.092% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -413.251% |
| LIDDS AB (publ) | 27.75 Million SEK | -2.07% |
| Lipum AB (publ) | 37.3 Million SEK | 24.072% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -290.493% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 79.158% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -72.711% |
| NextCell Pharma AB | -576.01 Thousand SEK | 5017.605% |
| OncoZenge AB (publ) | 15.9 Million SEK | -78.097% |
| Saniona AB (publ) | 1.07 Million SEK | -2530.115% |
| Simris Alg AB (publ) | 38.64 Million SEK | 26.695% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.189% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.079% |
| Xintela AB (publ) | 57.31 Million SEK | 50.579% |
| Ziccum AB (publ) | 27.87 Million SEK | -1.608% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -289.741% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.413% |
| CombiGene AB (publ) | 44.14 Million SEK | 35.832% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 80.19% |
| Intervacc AB (publ) | 79.78 Million SEK | 64.497% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.776% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 33.556% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -60.19% |
| Corline Biomedical AB | 30.16 Million SEK | 6.105% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 51.188% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 65.941% |
| Aptahem AB (publ) | 10.01 Million SEK | -182.897% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 78.97% |
| Fluicell AB (publ) | 28.61 Million SEK | 1.016% |
| Biovica International AB (publ) | 133.72 Million SEK | 78.817% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -43.135% |
| Abliva AB (publ) | 27.86 Million SEK | -1.652% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.361% |
| 2cureX AB (publ) | 36.51 Million SEK | 22.432% |
| I-Tech AB | 40.14 Million SEK | 29.445% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.704% |
| Cyxone AB (publ) | 28.21 Million SEK | -0.398% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 74.1% |
| Biosergen AB | 26.8 Million SEK | -5.66% |
| Nanologica AB (publ) | 69.88 Million SEK | 59.468% |
| SynAct Pharma AB | 224.49 Million SEK | 87.382% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 35.878% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.583% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -18.252% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.224% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -260.557% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.461% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -92.696% |